Inactive Instrument

Highlights Bavarian Nordic A/S CBOE EUROPE EQUITIES

Equities

DK0015998017

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^DKK	-

May. 31	Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	MT
May. 30	Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	May. 31	MT
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	May. 30	MT
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.	May. 08	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	May. 08	CI
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	Apr. 30	MT
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	Apr. 29	CI
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	Apr. 29	MT
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	Apr. 29	CI
Bavarian Nordic A/S's Equity Buyback announced on May 9, 2023, has expired.	Apr. 15	CI
Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	Mar. 13	MT
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	Mar. 13	CI
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Bavarian Nordic A/S Announces Accelerated Assessment for the Upcoming Marketing Authorisation Application for CHIKV VLP	Feb. 23	CI
Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024	Feb. 21	CI
Bavarian Nordic Confirms FY23 Revenue Growth Outlook	Nov. 16	MT
Bavarian Nordic A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023	Nov. 16	CI
Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk	23-10-25	CI
Bavarian Nordic Receives EUR11 Million Smallpox Vaccine Contract	23-09-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bavarian Nordic A/S CBOE EUROPE EQUITIES

Equities

DK0015998017

Highlights

Filters